Mirogabalin clinical trials
Also written DS-5565.
How each study uses mirogabalin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the mirogabalin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2015 (6)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 6 |
| 2019 | 2 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 6
Daiichi Sankyo Co., Ltd. (6) · Daiichi Sankyo (6) · Pusan National University Yangsan Hospital (1) · Cairo University (1) · Thammasat University Hospital (1) · Beijing Tiantan Hospital (1) · Bangladesh Medical University (1) · Gangnam Severance Hospital (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test mirogabalin.
- Mar 2027Efficacy and Safety of Mirogabalin in Diabetic Peripheral Neuropathic PainPhase 4 · Bangladesh Medical University
- Jun 2027The Efficacy and Safety of Pregabalin and Mirogabalin in Patients With FibromyalgiaNot applicable · Beijing Tiantan Hospital
- Jul 2027Perioperative Mirogabalin for Pain Relief After Modified Radical MastectomyNot applicable · Cairo University
Studies
Open first, then newest update. How each study uses mirogabalin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 18
- Perioperative Mirogabalin for Pain Relief After Modified Radical MastectomyNot yet recruitingNot applicableCairo UniversityNCT07880821Written as Mirogabalin
- Comparing Efficiency of Mirogabalin and Pregabalin in Primary TKARecruitingNot applicableThammasat University HospitalNCT06328062Written as Mirogabalin
- The Efficacy and Safety of Pregabalin and Mirogabalin in Patients With FibromyalgiaRecruitingNot applicableBeijing Tiantan HospitalNCT07157852Written as Mirogabalin
- Efficacy and Safety of Mirogabalin in Diabetic Peripheral Neuropathic PainRecruitingPhase 4Bangladesh Medical UniversityNCT07451431Written as Mirogabalin
- Mirogabalin for Total Hip ArthroplastyRecruitingNot applicableGangnam Severance HospitalNCT05938088Written as Arm I (mirogabalin group)
- Comparison of the Efficacy and Safety of Mirogabalin and Duloxetine in Chemotherapy-induced Peripheral Neuropathy in a Randomized Controlled Trial: a Quality of Life Study in Cancer SurvivorsCompletedNot applicablePusan National University Yangsan HospitalNCT06711978Written as Mirogabalin
- Study of Mirogabalin for Central Neuropathic PainCompletedPhase 3Daiichi Sankyo Co., Ltd.NCT03901352Written as Mirogabalin
- A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic PainCompletedPhase 3Daiichi Sankyo Co., Ltd.NCT04094662Written as Mirogabalin
- DS-5565 Phase III Study for Renal Impairment in Japanese SubjectsCompletedPhase 3Daiichi Sankyo Co., Ltd.NCT02607280Written as DS-5565
- Treatment of Neuropathic Pain Associated With Diabetic Peripheral NeuropathyCompletedPhase 2Daiichi SankyoNCT01496365Written as DS-5565 tablet
- Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney DiseaseCompletedPhase 3Daiichi SankyoNCT02496884Written as DS-5565
- Treatment of Pain Associated With FibromyalgiaCompletedPhase 3Daiichi SankyoNCT02146430Written as DS-5565
- Treatment of Pain Associated With FibromyalgiaCompletedPhase 3Daiichi SankyoNCT02187159Written as DS-5565
- Treatment of Pain Associated With FibromyalgiaCompletedPhase 3Daiichi SankyoNCT02187471Written as DS-5565
- DS-5565 Phase III Study for Diabetic Peripheral Neuropathic PainCompletedPhase 3Daiichi Sankyo Co., Ltd.NCT02318706Written as DS-5565
- DS-5565 Phase III Study for Post-herpetic NeuralgiaCompletedNot applicableDaiichi Sankyo Co., Ltd.NCT02318719Written as DS-5565
- An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With FibromyalgiaCompletedPhase 3Daiichi SankyoNCT02234583Written as DS-5565
- Asian Phase 2 Study for Treatment of Pain Associated With Diabetic Peripheral NeuropathyCompletedPhase 2Daiichi Sankyo Co., Ltd.NCT01504412Written as DS-5565
Given beside what is tested · 1 — mirogabalin is usual care or a partner of the new treatment
Codes
What other systems call mirogabalin · ClinicalTrials.gg INT000242
- MeSH (NLM) C000598618mirogabalinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) S7LK2KDM5UMIROGABALINConfirmed FDA, NLM, Wikidata
- Wikidata Q20706932mirogabalinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170186MirogabalinOne source FDA
- DrugBank DB11825One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000598618 | mirogabalin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | S7LK2KDM5U | MIROGABALIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q20706932 | mirogabalin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170186 | Mirogabalin | One source FDA |
| DrugBank | DB11825 | — | One source Wikidata |
Also registered as mirogabalin besylate (UNII 01F4FRP8YL).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.